trending Market Intelligence /marketintelligence/en/news-insights/trending/uyvmkldbsx98ynsynp8ymw2 content esgSubNav
In This List

GSK drops out of race for Pfizer's $20B consumer healthcare arm

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


GSK drops out of race for Pfizer's $20B consumer healthcare arm

GlaxoSmithKline Plc said it pulled out from the bidding battle to acquire Pfizer Inc.'s consumer healthcare business valued at $20 billion.

"While we will continue to review opportunities that may accelerate our strategy, they must meet our criteria for returns and not compromise our priorities for capital allocation," GSK CEO Emma Walmsley said in a news release.

According to recent reports, the British drugmaker was leading the auction for the Pfizer division, which sells branded over-the-counter products. Reckitt Benckiser Group Plc, which was only looking to acquire part of the business, also withdrew from the sale process.

GlaxoSmithKline shares were up 3.72% to £13.21 apiece as of 8:10 a.m. London time March 23.